CN117903264A

CN117903264A - Novel coronavirus SARS-CoV-2 HLA-A2 restriction epitope peptide and application

Info

Publication number: CN117903264A
Application number: CN202311409551.9A
Authority: CN
Inventors: 何晓波; 吴艳峰; 虞淦军; 李楠; 徐佳; 徐蓉蓉
Original assignee: Second Military Medical University SMMU
Current assignee: Second Military Medical University SMMU
Priority date: 2023-10-26
Filing date: 2023-10-26
Publication date: 2024-04-19

Abstract

Provided herein are novel coronavirus SARS-CoV-2HLa-a2 restriction epitope peptides and uses thereof. In particular, provided herein is an isolated polypeptide having the amino acid sequence IFLWLLWPV (SEQ ID NO: 2) which is a novel coronavirus SARS-CoV-2HLa-a2 restriction epitope polypeptide. Also provided herein are complexes, articles of manufacture, and uses thereof comprising the polypeptides. The related active substances and products of the application can be used for detecting, diagnosing, preventing and/or treating SARS-CoV-2 related diseases.

Description

Novel coronavirus SARS-CoV-2 HLA-A2 restriction epitope peptide and application

Technical Field

The present application relates to the field of immunology and biomedical. More particularly, the present application relates to SARS-CoV-2 virus HLA-A2 restriction epitope polypeptide (e.g., polypeptide of SEQ ID NO: 2), as well as to said epitope polypeptide and complexes, products and uses thereof, e.g., in the manufacture of products for the detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related disease.

Background

The SARS-CoV-2 genome is flanked by 5' and 3' untranslated regions, the 5' end comprising 2 longer Open Reading Frames (ORFs), encoding 16 nonstructural proteins; the remaining near 3' end of the genome encodes mainly structural proteins and other accessory proteins. The structural proteins of the virus mainly include spike protein (S protein), membrane glycoprotein (M protein), small envelope protein (envelope glycoprotein, E protein), nucleocapsid protein (nucleocapsid protein, N protein).

The S protein can bind host cells and mediate virus infection, is the main antigen protein for the research and development of antibodies and vaccines at present, but SARS-CoV-2 continuously accumulates mutation, especially mutation of structural protein, to generate a plurality of SARS-CoV-2 mutant strains with adaptability advantage, and the mutant strains usually have stronger infectious or pathogenic potential, and the mutation can cause the change of antigen characteristics, thereby affecting the prevention and treatment effects of preventive vaccines and therapeutic antibodies on the mutant strains and leading the virus to immune escape in the body. Based on genetic sequence analysis, structural protein mutations are mainly concentrated on the S protein and the N protein, which presents a great challenge to vaccines or antibodies developed based on S protein antigen information.

M protein is essentially a kind of transmembrane protein, and is structurally characterized by having three structural domains, namely an N-terminal extracellular domain, a three-transmembrane domain and an internal C-terminal domain, and plays an important role in the morphogenesis and maintenance of viruses, and is the most abundant glycoprotein in virus particles. More critical is that the M gene is relatively conserved, the frequency of mutation of the M protein is far lower than that of the S protein, and vaccines or antibodies developed based on the M protein are not easy to cause reduction of prevention and treatment effects due to virus mutation. Therefore, if the M protein is used as a target for immunization of an organism, on one hand, the organism can generate specific immune response aiming at the virus M protein, so that the organism can effectively remove viruses, measures are provided for preventing and treating SARS-CoV-2, and on the other hand, the relatively conservative low mutation characteristic can further avoid immune escape of the viruses caused by mutation, and the immune escape has a broader-spectrum effect.

The synthetic peptide vaccine is a new vaccine developed along with the development of molecular biology and immunology in recent years, can induce organisms to generate specific immune response, has slight side effect and good safety, is a popular direction of current vaccine research, and is widely applied to anti-tumor and antiviral immunotherapy. A variety of epitope polypeptide-based vaccines are currently in clinical research or market.

HLA-A 0201 is an MHC class I molecule with higher distribution in the population of China, the positive rate is between 40 and 60 percent, and the HLA-A 0201 is the first molecule of each subgroup of MHC class I molecules and is the first choice related molecule in vaccine design. At present, a plurality of HLA-A x 0201 restrictive CTL epitopes have been identified, and some have shown better curative effect in clinic. However, due to the diversity and complexity of cellular epitopes, intensive research into specific proteins is still required to develop epitope polypeptides for immune or therapeutic applications.

T2 cells are one of the tools for determining binding of epitopes to HLA-A 0201 molecules, which is a strain of HLA-A 0201-type cells deficient in antigen presenting transport, and express only HLA-A 0201 molecules free of endogenous antigen molecules on the cell surface, whereby the degree of binding to the peptide of interest can be used to determine the affinity between HLA-A 0201 molecules and the epitope of interest.

There remains a great need in the art to develop ways, products and methods that are effective in the prevention and treatment of the novel coronavirus SARS-CoV-2 and its related diseases.

Disclosure of Invention

It is the HLA-A2 restriction epitope polypeptide molecule of one of the M proteins of the main structural proteins of SARS-CoV-2 virus, which can bind with high affinity to HLA-A2 and has M protein specificity, and can be effectively applied to the preparation and development of downstream products.

In some aspects herein, there is provided an isolated polypeptide comprising the amino acid sequence: IFLWLLWPV (SEQ ID NO: 2). In some embodiments, the amino acid sequence of the isolated polypeptide of the application is IFLWLLWPV (SEQ ID NO: 2).

In some embodiments, the isolated polypeptide is a novel coronavirus SARS-CoV-2 epitope peptide, and the polypeptide is an HLA-A2 restriction epitope peptide.

In some embodiments, the isolated polypeptide is an M protein epitope peptide of SARS-CoV-2 and the polypeptide is an HLA-A x 0201 restriction epitope peptide.

In some embodiments, the affinity coefficient of the isolated polypeptide for the cell surface HLA-A x 0201 molecule is at least 2.0, e.g., at least 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0.

In some aspects herein, a complex is provided comprising an epitope polypeptide described in the present application.

In some embodiments, the complex is selected from: an antigen presenting cell comprising a protein or fusion protein or recombinant protein comprising an epitope polypeptide of the application loaded with an epitope polypeptide of the application.

In some embodiments, the antigen presenting cell is one or more selected from the group consisting of: dendritic cells, macrophages, B cells, fibroblasts, endothelial cells or cells obtained by artificial modification of any of the foregoing.

In some aspects herein, an isolated nucleic acid molecule is provided that encodes an epitope polypeptide of the application or a protein or fusion protein or recombinant protein comprising an epitope polypeptide of the application.

In some aspects herein, an article of manufacture is provided comprising an epitope polypeptide and/or complex herein.

In some embodiments, the article further comprises an acceptable carrier or excipient.

In some embodiments, the article is a composition or kit.

In some aspects herein, there is provided the use of a polypeptide, complex and/or article of manufacture of the application for the preparation of one or more products selected from the group consisting of: dendritic cells sensitized with the polypeptide, specific immune effector cells specific for the polypeptide, targeted drugs targeting the polypeptide, vaccines targeting the polypeptide, detection reagents targeting the polypeptide, or kits.

In some embodiments, the product is used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 associated disease.

In some aspects herein, there is provided a method of preparing a product selected from the group consisting of: a dendritic cell sensitized with a polypeptide, a specific immune effector cell specific for the polypeptide, a targeting drug targeting the polypeptide, a vaccine targeting the polypeptide, a detection reagent or kit for targeting the polypeptide, the method comprising:

(a) Providing a polypeptide, complex and/or article of manufacture described herein;

(b) The polypeptide, complex or preparation of (a) is used for the sensitization of the dendritic cells, the stimulation of the immune effector cells, or the preparation of the medicament, vaccine, detection reagent or kit.

In some embodiments, the resulting product is used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related disease.

In some aspects herein, there is provided a sensitized dendritic cell, a specific immune effector cell, a targeted drug, a targeted vaccine, a targeted detection reagent or a kit made with the method.

In some embodiments, the sensitized dendritic cells, specific immune effector cells, targeted drugs, targeted vaccines, targeted detection reagents or kits are used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases.

Any combination of the technical solutions and features described above can be made by a person skilled in the art without departing from the inventive concept and the scope of protection of the present invention. Other aspects of the invention will be apparent to those skilled in the art in view of the disclosure herein.

Drawings

The present invention will be further described with reference to the accompanying drawings, wherein these drawings are provided only for illustrating embodiments of the present invention and are not intended to limit the scope of the present invention.

Fig. 1: SMp-2 epitope polypeptides have high affinity to HLA-A x 0201 molecules. Table 1 shows the results of a flow assay for predicting binding of an epitope peptide to HLA-A 0201 molecules, with higher fluorescence coefficients representing higher affinity of the epitope peptide to HLA-A 0201 (generally, higher fluorescence coefficients than 1 represent high affinity of the epitope peptide to HLA-A 0201).

Fig. 2: the murine DC immunized transgenic mice sensitized with the epitope peptide induced a specific immune response against the epitope. The figure shows analysis of Elispot results (", P <0.0001," ns "= no significant difference).

Fig. 3: mature SMp-2 epitope polypeptide sensitized human Dendritic Cells (DCs) were successfully induced in vitro. The figure shows the expression strength of DC cell surface maturation marker molecules after induced culture by flow detection SMp-2.

Fig. 4: SMp-2 sensitized human DC induced effector T lymphocytes have SMp-2 epitope specific killing effect. The graph shows that CFSE/7-AAD flow assay analysis induced SMp-2 specific CTL killing (", P < 0.001", P <0.0001, "ns" = no significant difference).

Fig. 5: SMp-2 specific human CTLs have a higher proportion in sensitized Dendritic Cell (DC) induced effector T cells. The figure shows the results of a tetra mer flow assay (OVA-loaded tetra mer as a flow control).

Fig. 6: SMp-2 specific human CTL can specifically secrete killer cell factor IFN-gamma under the stimulation of target cells. The figure shows analysis of Elispot results (", P <0.0001," ns "= no significant difference) (target cells loaded with irrelevant peptide OVA as control group).

Detailed Description

The application discovers and develops that one M protein of main structural proteins of SARS-CoV-2 virus can bind HLA-A2 molecule with high affinity, and can be effectively applied to the preparation and development of downstream products.

Based on deep analysis of SARS-CoV-2 novel coronavirus M protein, several SARS-CoV-2 candidate antigen peptides which can be combined with HLA-A.0201 and induce body to produce CTL are selectively synthesized, through T2 peptide combination experiment, epitope peptide with strong affinity with HLA-A.0201 is screened out, and its immunogenicity is evaluated, so that it can induce specific HLA-A.0201 limited cytotoxic T lymphocyte in HLA-A.0201 healthy human peripheral blood, and is an immunogenic polypeptide naturally processed and presented by cell. Identification of HLA-A2 restricted cytotoxic T lymphocyte epitope peptide derived from SARS-CoV-2 novel coronavirus M protein has important significance for research of pathogenesis of SARS-CoV-2 and development of vaccine and therapeutic preparation.

The features mentioned in the description or the features mentioned in the examples can be combined. All of the features disclosed in this specification may be combined with any combination of the features disclosed in this specification, and the various features disclosed in this specification may be substituted for any alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the disclosed features are merely general examples of equivalent or similar features.

All numerical ranges provided herein are intended to expressly include all values and ranges of values between the endpoints of the range. For example, 1-3 includes endpoints 1 and 3, specific integer number points 2 and non-integer number points therein (e.g., without limitation, 1.2, 1.5, 1.8, 2.1, 2.3, 2.4, 2.8, etc.), and sub-ranges thereof (e.g., without limitation, 1-2, 2-3, 1-1.2, 1.5-1.8, etc.).

As used herein, "comprising," having, "or" including "includes" including, "" consisting essentially of … …, "" consisting essentially of … …, "and" consisting of … …; "consisting essentially of … …", "consisting essentially of … …" and "consisting of … …" are under the notion of "containing", "having" or "including".

As used herein, "polypeptide of the invention," "specific (poly) peptide," "HLA-A 2-restricted epitope (poly) peptide," and "SARS-CoV-2 HLA-A 2-restricted epitope (poly) peptide" are used interchangeably to refer to epitope peptides derived from the SARS-CoV-2-based M protein that have high affinity for HLA-A 2.

The functional epitope polypeptide of the present application may comprise or be a polypeptide of SEQ ID NO. 2. The polypeptides of the application may be naturally purified products, or chemically synthesized products, or produced from prokaryotic or eukaryotic hosts (e.g., bacterial, yeast, higher animal, insect, and mammalian cells) using recombinant techniques.

As used herein, the term "epitope polypeptide coding sequence" or "epitope polypeptide coding molecule" refers to a sequence that encodes an epitope polypeptide herein or an active fragment thereof. After obtaining the amino acid sequence of the epitope polypeptide of the present application, one of ordinary skill in the art can obtain its coding sequence and optimize its sequence using methods known in the art. For example, the epitope polypeptide coding sequence may be obtained from the full-length coding sequence or CDS sequence corresponding to SARS-CoV-2M protein. The coding sequences of the application may also include molecules that hybridize to these sequences under stringent conditions, or family gene molecules that are highly homologous to the above-described molecules.

As used herein, the term "stringent conditions" refers to: (1) Hybridization and elution at lower ionic strength and higher temperature, e.g., 0.2 XSSC, 0.1% SDS,60 ℃; or (2) adding denaturing agents such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll,42℃and the like during hybridization; or (3) hybridization only occurs when the identity between the two sequences is at least 50%, preferably 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, or 90% or more, more preferably 95% or more. For example, the sequence may be the complement of the sequence defined in (a).

The polypeptides of the invention may also be present in a variety of forms, as desired. The epitope polypeptides of the invention may be present alone, or may be conjugated or fused with other proteins or polypeptides to form a polypeptide complex, or may be loaded into antigen presenting cells, or may be present in the form described above in preparations such as compositions or kits.

In some embodiments, the epitope polypeptides herein may be included in a fusion peptide, e.g., the portion fused thereto includes: proteins of viral or host origin, transferrin (Fn), HIV p24, stem of envelope viruses, such as influenza HA2, gp41 of aids virus, antibody Fc-segment, GM-CSF, IL-21, CD40L or CD40 antibodies.

In some embodiments, the fusion peptide may further comprise: signal peptide, linker peptide, tag, etc. For example, the signal peptide may be selected from: protein itself, CD33, CD8, CD16, mouse IgG1 antibody, influenza HA. The linker peptide may be selected from ：(G4S)₃、(G4S)_n、GSAGSAAGSGEF、(Gly)₆、EFPKPSTPPGSSGGAP、KESGSVSSEQLAQFRSLD、(Gly)₈、EGKSSGSGSESKST. tags may be selected from ：His-tag、AviTag、Calmodulin tag、polyglutamate tag、E-tag、FLAG tag、HA-tag、Myc-tag、S-tag、SBP-tag、Sof-tag 1、Sof-tag3、Strep-tag、TC tag、V5 tag、T7 tag、VSV tag、Xpress tag、3X FLAG tag、Isopep tag、Spytag、Snoop tag and PNE tag.

In some embodiments, the epitope polypeptides of the application may be conjugated to a BSA-equivalent molecular weight protein, thereby forming a polypeptide conjugate. Typically, the conjugate consists of a polypeptide, a cross-linking agent, preferably glutaraldehyde, EDAC, and BSA. For another example, an epitope polypeptide of the application may be loaded into an antigen presenting cell of an epitope polypeptide of the application. In some embodiments, the antigen presenting cell is one or more selected from the group consisting of: dendritic cells, macrophages, B cells, fibroblasts, endothelial cells or cells obtained by artificial modification of any of the foregoing.

The polypeptides, complexes and/or articles of the application can be used to prepare a variety of products. The product may include, but is not limited to, one or more selected from the group consisting of: dendritic cells sensitized with the polypeptide, specific immune effector cells specific for the polypeptide, targeted drugs targeting the polypeptide, vaccines targeting the polypeptide, detection reagents or kits targeting the polypeptide, e.g. for preparing immune or pharmaceutical compositions directly as immunogens with the polypeptide.

The invention also provides a medicament, a pharmaceutical composition or a kit, which contains an effective amount of the epitope polypeptide, the complex or the product prepared by adopting the epitope polypeptide, the complex or the product and a pharmaceutically or immunologically acceptable carrier.

In preferred embodiments, the pharmaceutical compositions are useful for detecting, diagnosing, preventing and/or treating a disease associated with SARS-CoV-2, chronic diseases caused thereby, and/or conditions thereof. For example, the pharmaceutical composition of the present invention can be used for preventing or treating infectious diseases or symptoms caused by novel coronaviruses, such as lung or other tissue injuries, complications, multi-organ failure, etc. caused by the novel coronaviruses.

In some embodiments, the products herein may be used to prevent, eliminate, or reduce a novel coronavirus infection or at least one symptom thereof in a subject, such as respiratory symptoms (e.g., nasal obstruction, sore throat, hoarseness), headache, cough, sputum, fever, wheezing, dyspnea, pneumonia due to infection, severe acute respiratory syndrome, renal failure, and the like.

As used herein, the term "comprising" or "including" includes "comprising," consisting essentially of … …, "and" consisting of … …. As used herein, the term "acceptable" ingredients are substances that are suitable for use in humans and/or animals and/or other subjects (e.g., cells) without undue adverse reactions (e.g., toxicity, irritation, and allergic response), commensurate with a reasonable benefit/risk ratio. As used herein, the term "effective amount" refers to an amount that is functional or active in humans and/or animals and/or other subjects (e.g., cells) and acceptable to the subject.

As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, and may include various excipients and diluents. The term refers to such agent carriers: they are not per se essential active ingredients and are not overly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art and a sufficient discussion of pharmaceutically acceptable excipients can be found in Remington pharmaceutical sciences (Remington's Pharmaceutical Sciences, mack Pub.Co., N.J.1991).

Acceptable carriers in the compositions can contain liquids such as water, saline, glycerol, and ethanol. In addition, auxiliary substances such as fillers, disintegrants, lubricants, glidants, effervescent agents, wetting or emulsifying agents, flavoring agents, pH buffering substances, etc. may also be present in these carriers. Typically, these materials are formulated in a nontoxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is typically about 5 to 8, preferably about 6 to 8.

The active substances in the composition of the invention account for 0.001 to 99.9 weight percent of the total weight of the composition; preferably 1 to 95wt%, more preferably 5 to 90wt%, and even more preferably 10 to 80wt% of the total weight of the composition. The rest is pharmaceutically acceptable carrier and other additives.

As used herein, the term "unit dosage form" refers to a dosage form that is required to prepare a composition of the present invention for administration in a single administration, including but not limited to various solid (e.g., tablet), liquid, capsule, sustained release formulations.

In another preferred embodiment of the invention, the composition is in unit dosage form or multiple dosage form. In another preferred embodiment of the invention, 1 to 6 doses of the composition of the invention, preferably 1 to 3 doses, are administered daily; most preferably, the daily dosage is 1 dose.

It will be appreciated that the effective dose of the active agent used may vary with the severity of the subject to be administered or treated. The specific conditions are determined according to the individual condition of the subject (e.g., the subject's weight, age, physical condition, effect to be achieved), which is within the scope of judgment of a skilled physician.

The composition of the invention can be solid (such as granules, tablets, freeze-dried powder, suppositories, capsules, sublingual tablets) or liquid (such as oral liquid) or other suitable shapes. The administration route can be as follows: (1) direct naked protein injection method; (2) Attaching an active substance to the transferrin/poly-L-lysine complex to enhance its biological effect; (3) Forming a complex of the active substance and positively charged lipid to overcome the difficulty of crossing cell membranes caused by negative charge of the phosphate backbone; (4) liposome-entrapped administration; (5) Binding to cholesterol increases its cytoplasmic retention time by a factor of 10; (6) Specific transport to target tissue and target cells using immunoliposome transport; (7) in vitro transfection; (8) electroporation (electroporation) into target cells.

Examples

The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. Appropriate modifications and variations of the invention may be made by those skilled in the art, and are within the scope of the invention.

The experimental methods described in the following examples, in which specific conditions are not specified, may be employed by conventional methods in the art, for example, with reference to the "molecular cloning Experimental guidelines" (third edition, new York, cold spring harbor laboratory Press, new York: cold Spring Harbor Laboratory Press, 1989) or according to the conditions recommended by the supplier. Methods for sequencing DNA are routine in the art and can also be provided for testing by commercial companies.

Percentages and parts are by weight unless otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred methods and materials described herein are presented for illustrative purposes only.

Example 1: affinity identification of SMp-2 epitope peptides with HLA-A x 0201 molecules

Peptide binding experiments were used to screen epitope peptides with high affinity to HLA-A x 0201. T2 cells (rich biotechnology, FH 0150) were first collected, washed three times with serum-free 1640 medium, and cell concentration was adjusted to 2×10 ⁶ cells/ml, plated in 24 well plates, 1 ml/well. Then incubated with 50. Mu.M of the candidate polypeptide and 3. Mu.g/ml of beta.2 microglobulin in a 5% CO ₂ incubator at 37℃for 18h. The incubated cells were washed three times with ice PBS, PE-labeled HLA-A 2-specific flow antibody (Biolegend Inc) was added, incubated at 4℃for 30min, and the average fluorescence intensity was measured by flow cytometry after PBS washing. The HLA-A2 restrictive influenza virus epitope polypeptide GILGFVFTL is used as a positive control, and the non-peptide stimulated simple T2 cells are used as a background control.

And (3) result judgment: the binding condition of the peptide and HLA-A 0201 molecule is detected by flow cytometry, and is based on that the binding of exogenous polypeptide and the MHC class I molecule on the surface of T2 cells can increase the expression quantity of the MHC class I molecule on the surface, and the more stable the binding of the exogenous polypeptide and the MHC class I molecule, the more the expression quantity of the MHC class I molecule can be detected, and the average fluorescence intensity is taken as a detection index. The result is a fluorescence coefficient (FI) as a measure. FI >1 of the polypeptide is considered to be a high affinity epitope.

The fluorescence coefficient (FI) is calculated as follows:

According to this method, the HLA-A2 high affinity epitope polypeptide is selected from the membrane glycoprotein M protein (SEQ ID NO: 11), spike glycoprotein S protein (SEQ ID NO: 12), envelope protein E protein (SEQ ID NO: 13), and nucleocapsid protein N protein (SEQ ID NO: 14) of SARS-CoV-2 coronavirus. The average fluorescence intensity and fluorescence coefficient of exemplary epitope peptides involved in the screening can be seen in table 1 and fig. 1:

TABLE 1 fluorescence coefficient FI after flow detection of binding of different epitope peptides to T2 cell surface HLA-A 0201 molecules

Results: the affinity results of exemplary candidate epitope polypeptides with HLA-A x 0201 molecules are shown in table 1, and the results show that polypeptide epitopes No. 1,2, 4 and 9 (respectively named SMp-1, SMp-2, SSp-4 and SSp-9) are ranked in front, the average fluorescence intensities are all greater than 10000, the fluorescence coefficients FI are all greater than 1, and even all more than 2.0; of these, SMp-2 epitope IFLWLLWPV has the highest FI, reaching 2.34.

Conclusion: polypeptide epitopes with high affinity with HLA-A x 0201 molecules are obtained through screening, and the top four polypeptide epitopes (1, 2,4 and 9) are selected for further screening and identification.

Example 2: IFN-gamma secretion detection of epitope peptide sensitized DC immune HLA-A2 transgenic mouse spleen cells

The 4 potential polypeptide epitopes (epitope peptides 1,2, 4, 9) obtained were screened according to example 1 and their immunogenicity was further tested in HLA-A2 transgenic mice. Bone marrow derived Dendritic Cells (DCs) were prepared from HLA-A2.1/K ^b transgenic mice (Jackson Laboratory, 003475) by conventional methods. After the mice were neck-removed and sacrificed, the femur and tibia were removed, PBS was withdrawn with a 1ml syringe and a needle was inserted into the bone marrow cavity to flush out bone marrow, then bone marrow erythrocytes were lysed using Tris-NH ₄ Cl solution, the supernatant was discarded by centrifugation and DCs were induced in 1640 medium containing 10% FBS, 1ng/ml mouse IL-4 (PeproTech, 214-14-5 UG), 10ng/ml mouse GM-CSF (PeproTech, 315-03-50 UG). Collecting DC cultured until 5 days, regulating cell concentration to 1× ⁶/ml, adding epitope peptide (final concentration 20 μg/ml), continuously culturing at 37deg.C in 5% CO ₂ incubator until 6 days, adding TNF-alpha (30 ng/ml) to stimulate maturation, and culturing until eighth day to obtain epitope peptide sensitized DC cell.

Peptide-sensitized DCs were collected, washed three times with PBS and cell concentrations were adjusted to 1X 10 ⁷/ml. Each male transgenic mouse was subcutaneously injected into the abdomen with 0.1ml for three total immunizations, spaced one week apart. Mice injected subcutaneously with either DC or PBS without epitope peptide were incubated as negative control mice. 7 days after the last immunization, spleens (sensitized DC group, empty DC group, PBS group) of each group of mice were picked up by aseptic operation, and erythrocytes were lysed to prepare single cell suspensions. Spleen cell suspensions (1X 10 ⁶/ml) were added to ELISPOT pre-coated plates (MabTech Inc), 200. Mu.l per well, and stimulated with the corresponding epitope peptide (final concentration 20. Mu.g/ml) for 24h. Spleen cells stimulated with PMA (daryou 2030421) were used as positive stimulation control wells. After the culture is finished and the cells are emptied, the cells are washed by PBS for 5 times, then the color development liquid is added for color development, and after the cells are sufficiently dried, the counting and the statistical analysis are performed by a plate reader.

Results: the Elispot assay results are shown in FIG. 2. The results indicate that SMp-2 (epitope peptide 2) sensitized DC immunized mice can secrete significantly increased amounts of IFN-gamma spots under stimulation of SMp-2 epitope peptide compared to negative control (non-sensitized DC or PBS immunized mice). While the secretion of the other three epitope peptides (epitope peptides 1, 4, 9) was not significantly increased compared to the control.

Conclusion: in view of the complexity of in vivo functions of organisms, whether a polypeptide epitope with high affinity to HLA-A x 0201 molecule is able to effectively sensitize DCs and thus the ability to effectively induce immune responses in vivo is unpredictable, and in vivo tests are required to verify their DC sensitization and specific immune induction effects. The in vivo test of the embodiment proves that the SMp-2 epitope polypeptide can effectively sensitize DC, and can extremely obviously induce specific IFN-gamma immune response aiming at the SMp-2 epitope in a mouse.

Example 3: characterization of SMp-2 epitope peptide-sensitized DC cells

Peripheral blood mononuclear cells of healthy humans were isolated, PBMC were resuspended in RPMI1640 serum-free medium, sampled and counted, cell densities were adjusted to 5X 10 ⁶/ml, 2ml were plated per well in 6-well plates and incubated overnight at 37℃at 5% CO ₂ concentration. Shaking and blowing off cells (mainly lymphocytes) which are not adhered to the wall in the next day, and collecting and freezing; the adherent cells were monocytes, and 2ml of complete medium containing human recombinant GM-CSF (50 ng/ml) and human recombinant IL-4 (10 ng/ml) was added to each well of a six well plate, and 2ml of the same medium was fed every other day. Immature dendritic cells (DENDRITIC CELLS, DC) induced to differentiate by monocytes were collected until day five, SMp-2 epitope peptide was added to 20 μg/ml, human TNF- α was added to 10ng/ml for stimulation of maturation at day six, and cultured until day eight to obtain SMp-2 epitope peptide sensitized mature DC cells.

Mature DC cells were resuspended to 1X 10 ⁶/100. Mu.l in PBS, 1. Mu.l each of FITC-CD80, PE-CD83, APC-CD86 flow-through antibodies (Biolegend Inc) were added, mixed well, incubated at 4℃for 30 minutes in the absence of light, washed once with PBS and examined by flow cytometry for expression of CD80, CD83, CD86 molecules characteristic of mature DC (FIG. 3).

Results: the expression of the SMp-2 epitope peptide sensitized DC cell characteristic surface molecule is shown in figure 3, and the result shows that the SMp-2 epitope peptide sensitized DC surface after stimulation of maturation has high expression of CD80, CD83 and CD86 characteristic molecules.

Conclusion: mature SMp-2 peptide sensitized DC cells can be successfully induced in vitro by adopting SMp-2 epitope peptide.

Example 4: SMp-2 specific humanized CTL induction culture and specific killing effect detection

Autologous T cells and dendritic cells were isolated from commercially available human PBMC cells (s 2001002) using conventional methods, and the cultured T cells were stimulated once a week with mature SMp-2 sensitized autologous dendritic cells, and co-stimulated three times. After three weeks of culture and expansion, effector cells were collected and tested for their specific killing effect by CFSE/7-AAD.

T2 cells loaded with SMp-2, T2 cells loaded with OVA polypeptide (SEQ ID NO:15, SIINFEKL, i.e.OVA _257-264) and empty T2 cells not loaded with polypeptide were used as target cells, respectively, labeled with CFSE working solution for 15 minutes (200. Mu.l CFSE/2X 10 ⁶ cells) at 37℃were incubated, washed once with complete medium, and the cell concentration was adjusted to 1X 10 ⁵ cells/ml with complete medium, and added to 96-well round bottom plates at 100. Mu.l per well.

Effector cells were added at three different target ratios of 10:1, 5:1, 2.5:1, loaded SMp-2, OVA _257-264 or empty T2 cells without effector cells were used as background control, incubated at 37℃for 4 hours, collected by centrifugation, labeled with 7-AAD working solution for 15 minutes at 4℃and resuspended after washing twice with PBS, and CFSE and 7-AAD fluorescent signals were detected by flow cytometry.

The calculation formula of the killing rate is as follows:

killing rate (%) = experimental group CFSE-7AAD double positive cells (%) -background group CFSE-7AAD double positive cells (%)

Results: the result of the CFSE/7-AAD killing detection method is shown in figure 4, and the result shows that SMp-2 sensitized DC can effectively induce T lymphocytes, so that the T lymphocytes can show significantly improved killing efficiency on target cells loaded with SMp-2 epitope peptide compared with control groups (simple T2 cells or T2 cells loaded with irrelevant peptide).

Conclusion: epitope peptide SMp-2 was able to effectively sensitize DCs and induce the production of effector T lymphocytes with excellent SMp-2 epitope-specific killing.

Example 5: detection of the proportion of SMp-2-specific human CTLs in vitro induced effector T cells

Mu.l of the peptide FLEX-T ^TM Tetramer monomer (Biolegend Inc; 280003) was mixed with 20. Mu. l SMp-2 epitope peptide (400. Mu.M), placed on ice and irradiated with ultraviolet light (366 nm) for 30 minutes, followed by incubation at 37℃for 30 minutes in the dark, after which 3.3. Mu.l of PE-streptavidin (Biolegend Inc) was added, mixed and placed on ice and incubated in the dark for 30 minutes, and finally 2.4. Mu.l of blocking solution were added (blocking solution: 1.6. Mu.l 50mM D-biotin+6. Mu.l 10% (w/v) NaN ₃ +192.4. Mu.l PBS) and the similarly prepared IV carrying OVA polypeptide (SIINFEKL, OVA _257-264, SEQ ID NO: 15) was used as an irrelevant peptide control.

Effector T cells induced in vitro as in example 4 were resuspended at 2X 10 ⁶/200. Mu.l in PBS, 2. Mu.l of SMp-2-Tetramer or OVA-Tetramer prepared were added, mixed well, incubated at 4℃for 30 minutes in the absence of light, washed once with PBS and examined by flow cytometry for the proportion of SMp-2-specific CTLs bound to SMp-2-Tetramer.

Results: the results of the Tetramer assay for SMp-2 specific CTLs are shown in FIG. 5, which shows that the proportion of SMp-2 specific CTLs in SMp-2 sensitized DC-induced cultured effector T cells reaches 3.64%, whereas the unrelated peptide control group is only 0.27%.

Conclusion: epitope peptide SMp-2 can effectively sensitize DC and further induce significant increase of SMp-2 specific humanized CTL proportion in effector T cells, thereby inducing specific T cell immune response to the SMp-2 epitope.

Example 6: IFN-gamma cytokine secretion assay for SMp-2 specific human CTL

Effector T cells induced in vitro as in the previous method were resuspended at 2X 10 ⁶ per ml with complete medium and 100 μl per well was added to the ELISPOT pre-coated plate. ELISPOT pre-coated plates (MabTech Inc) were added at different effective target ratios (1:0.1, 1:0.25, 1:0.5) using SMp-2 loaded T2 cells, OVA polypeptide (SIINFEKL, OVA _257-264) loaded T2 cells, and polypeptide-unloaded, empty T2 cells as stimulation cells, respectively, with cell concentrations adjusted to 1X 10 ⁶/ml in complete medium. And taking the loaded SMp-2, OVA _257-264 or empty T2 cells without effector cells as a background control group, incubating for 24 hours at 37 ℃, cleaning the cells for 5 times by using PBS, adding a chromogenic solution for developing color, and counting the number of the IFN-gamma spots displayed by using a plate reader and carrying out statistical analysis after full drying. Based on the proportion of CD8 positive T cells and the number of IFN-gamma spots in the effector T cells, the proportion of CTL cells secreting IFN-gamma was calculated.

The ratio of IFN-gamma secreting CTL cells was calculated as follows:

Results: the Elispot assay results are shown in FIG. 6. The results show that induced SMp-2 specific CTLs have significantly improved IFN- γ secretion under stimulation of target cells loaded with SMp-2 epitope peptide compared to control groups (T2 cells alone or T2 cells loaded with unrelated peptide), and that the CTL secreting IFN- γ account for up to 2.3% under stimulation of the lowest proportion of stimulated cells.

Conclusion: epitope peptide SMp-2 can effectively sensitize DC and further induce SMp-2 specific CTL to specifically and efficiently secrete IFN-gamma under the stimulation of target cells, so that specific IFN-gamma immune response aiming at the SMp-2 epitope is induced.

While the preferred embodiments of the present application have been described in detail, the present application is not limited to the embodiments, and various equivalent modifications and substitutions can be made by those skilled in the art without departing from the spirit of the present application, and these equivalent modifications and substitutions are intended to be included in the scope of the present application as defined in the appended claims.

Sequence information

Claims

1. An isolated polypeptide having the amino acid sequence IFLWLLWPV (SEQ ID NO: 2).

2. The polypeptide of claim 1, wherein the polypeptide is a novel coronavirus SARS-CoV-2 epitope peptide and the polypeptide is an HLA-A2 restriction epitope peptide.

3. The polypeptide of claim 1, wherein the polypeptide is a SARS-CoV-2M protein epitope peptide and the polypeptide is an HLA-A x 0201 restriction epitope peptide.

4. A polypeptide according to claim 1, wherein the polypeptide has an affinity coefficient for a cell surface HLA-A x 0201 molecule of at least 2.0, e.g. at least 2.2, at least 2.5, at least 2.9.

5. A complex comprising the polypeptide according to claim 1 to 4,

For example, the complex is selected from: a protein or fusion protein or protein conjugate comprising the polypeptide of any one of claims 1-4; an antigen presenting cell loaded with the polypeptide of any one of claims 1 to 4.

6. The complex of claim 5, wherein the antigen presenting cell is one or more selected from the group consisting of: dendritic cells, macrophages, B cells, fibroblasts, endothelial cells or cells obtained by artificial modification of any of the foregoing.

7. An article of manufacture comprising a polypeptide according to any one of claims 1 to 4 and/or a complex according to any one of claims 5 to 6,

For example, the article is a composition or kit.

8. Use of the polypeptide according to any one of claims 1 to 4, the complex according to any one of claims 5 to 6 or the article according to claim 7 for the preparation of one or more products selected from the group consisting of: dendritic cells sensitized with the polypeptide, specific immune effector cells specific for the polypeptide, targeted drugs targeting the polypeptide, vaccines targeting the polypeptide, detection reagents or kits targeting the polypeptide,

For example, the product is useful in the detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related disease.

9. A method of preparing a product selected from the group consisting of: a dendritic cell sensitized with the polypeptide of any one of claims 1-4, a specific immune effector cell specific for the polypeptide, a targeting drug targeting the polypeptide, a vaccine targeting the polypeptide, a detection reagent or kit targeting the polypeptide, the method comprising:

(a) Providing a polypeptide according to any one of claims 1 to 4, a complex according to any one of claims 5 to 6 or an article according to claim 7;

(b) The polypeptide, complex or preparation described in (a) is used for the sensitization of the dendritic cells, the stimulation of the immune effector cells, or the preparation of the medicament, vaccine, detection reagent or kit,

10. A sensitized dendritic cell, a specific immune effector cell, a targeted drug, a targeted vaccine, a targeted detection reagent or a kit prepared by the method of claim 9, which is used for detection, diagnosis, prevention and/or treatment of SARS-CoV-2 related diseases.